Researchers Develop Smart Cancer Drug That Could Reduce Need for Chemotherapy - Video

Scientists in India have developed a promising "smart" cancer drug designed to activate primarily inside cancer cells while limiting damage to healthy tissue.

The findings, published in the ACS Journal of Medicinal Chemistry, represent an early step toward developing cancer treatments that can be switched on specifically within tumors.

The drug, RK-251, was developed through collaborative research led by Institute of Advanced Study in Science and Technology (IASST), an autonomous institute under India’s Department of Science & Technology, and Indian Institute of Technology Guwahati.

Unlike conventional chemotherapy, which can damage healthy cells along with cancer cells, RK-251 is designed to remain relatively inactive until it reaches an environment characteristic of tumors.

The approach takes advantage of a feature commonly associated with cancer cells: elevated levels of reactive oxygen species (ROS). When RK-251 enters a cancer cell with high ROS levels, these molecules trigger the drug to release NBDHEX, a potent anticancer compound.

NBDHEX works by blocking proteins that cancer cells rely on for survival and resistance to treatment. This could potentially allow the drug to attack tumor cells more selectively while reducing unwanted effects on healthy tissue.

In preclinical experiments, RK-251 demonstrated strong anticancer activity against aggressive triple-negative breast cancer cells, while showing substantially less activity against healthy cells.

Researchers also evaluated the drug candidate in zebrafish embryos (Danio rerio). The experiments showed no obvious signs of toxicity and demonstrated the expected fluorescence when ROS were present, providing additional evidence that the ROS-responsive mechanism was functioning as intended.

However, RK-251 remains a preclinical drug candidate. Results from cancer cells and animal models cannot establish whether the drug will be safe or effective in humans. Further laboratory studies, animal testing and eventually carefully controlled clinical trials will be required before it could become a treatment option for patients.

REFERENCE: Rahul Kesarwani, Nikita Pal, Dorothy Das, Asis Bala, Krishna P. Bhabak; Rational Development of Activatable Prodrugs of the GSTP1 Inhibitor NBDHEX: Turn-On NIR Fluorogenic Drug Delivery with Selective Anticancer Activity. J. Med. Chem. 23 July 2026; https://doi.org/10.1021/acs.jmedchem.6c01286